Sanjukta Bhattacharya
Founder of Atlas Discovery, AI-native pharma company
Company
Sanjukta Bhattacharya is listed as a founder of Atlas Discovery. AI-native pharma company
Founder traction evidence
Public posts and activity attributed directly to this founder.
- X
We’re building foundation models that predict patient response in clinical trials. Excited for the future at @atlasdiscovery0 with @ShaamilKarim1 and @Cgensbigler ! Quote Atlas Discovery @atlasdiscovery0 · Jun 23 Nine out of ten drugs fail in clinical trials. The reason isn't a shortage of data. It's that none of it connects. We started Atlas Discovery to fix that with foundation models of patient drug response. We're backed by @ycombinator, @pearvc, and more.
We’re building foundation models that predict patient response in clinical trials. Excited for the future at @atlasdiscovery0 with @ShaamilKarim1 and @Cgensbigler ! Quote Atlas Discovery @atlasdiscovery0 · Jun 23 Nine out of ten drugs fail in clinical trials. The reason isn't a...
- X
We were curious whether the autoregressive next token prediction recipe that has worked for language can be applied to single-cell biolog...
We were curious whether the autoregressive next token prediction recipe that has worked for language can be applied to single-cell biology. We first tried to understand if a discrete representation is the right substrate for modelling in this domain? Tldr: Yes! We studied a...
- X
We’re sharing a first look at ClinicBench! A benchmark for how well AI agents can make clinical decisions from a patients medical history.
We’re sharing a first look at ClinicBench! A benchmark for how well AI agents can make clinical decisions from a patients medical history. Interestingly, GPT 5.6 sol >>
- X
New ways of quantifying cellular states are coming up everyday, with different granularities & modalities of information.
New ways of quantifying cellular states are coming up everyday, with different granularities & modalities of information. AI cell models that we know of today use RNA-seq as the primary modality of learning - simply due to the ease and abundance of capturing this. I've been
- X
I spend most of my days working with millions of samples across tissues, diseases, and perturbations.
I spend most of my days working with millions of samples across tissues, diseases, and perturbations. Here’s how it goes: months go into defining an objective - it’s pretty much defined over the latent space a model has learned - so you’re just trying to get the model to...
- X
Updated the leaderboard with Opus 5.
Updated the leaderboard with Opus 5. Check out ClinicBench for more details! We benchmark how good agents are to make clinical decisions from a patient's medical history.
- X
I remember reading @agupta ‘s article on coin mints almost a year back now.
I remember reading @agupta ‘s article on coin mints almost a year back now. Thanks for the shoutout! It’s incredibly rewarding how the idea of moving trials forward using foundation models and AI agents is becoming a reality at @atlasdiscovery0
- X
A very meaningful, early milestone for us at @atlasdiscovery0 .
A very meaningful, early milestone for us at @atlasdiscovery0 . Grateful to Alliance to Cure for partnering with us to pursue a new treatment possibility for CCM.